Insider purchase details
Sanjay K. Shetty, who serves as president of CenterWell at Humana Inc. (NYSE: HUM), acquired 810 shares of Humana common stock on February 23, 2026. The shares were purchased at $185.205 apiece, for a total transaction value of $150,016.
At the time of the filing, Humana shares were trading at $176.96, close to the stocks 52-week low of $169.61. According to InvestingPro analysis, Humana appears undervalued at current levels, with comprehensive insights available in the companys Pro Research Report.
Current holdings and option position
After this purchase, Shetty directly holds 11,657 shares of Humana stock. That total includes 8,818 restricted stock units that represent a contingent right to receive one share of Humana common stock each.
Shetty also maintains exercisable options to acquire additional shares: options for 3,964 shares at an exercise price of $487.1602 that expire on April 1, 2030, and options for 6,572 shares at an exercise price of $367.21 that expire on February 21, 2031.
Corporate developments and financial moves
Humana has declared a quarterly cash dividend of $0.885 per share, payable on April 24, 2026, to shareholders of record as of March 27, 2026.
Separately, Humanas healthcare services arm, CenterWell, completed the acquisition of MaxHealth. The transaction brings 54 primary care clinics into the CenterWell network and expands its footprint to serve more than 120,000 patients in Florida.
On the community side, Humana has committed in excess of $1.7 million to healthcare-related initiatives in Illinois, with funding targeted at areas such as housing stability and improving access to healthcare.
Analyst views
Analyst coverage remains mixed. UBS reiterated a Neutral rating on Humana with a price target of $195, highlighting the importance of sustaining margins for Medicare Advantage members. Barclays reduced its price target to $176 and flagged caution regarding the companys expectation of doubling Medicare Advantage margins.
What this means
The insider purchase increases Shettys direct stake in Humana and comes amid several company actions: a clinic acquisition, a scheduled dividend, and community funding. Analyst commentary underscores margin durability in Medicare Advantage as a focal point for investors assessing Humanas near-term outlook.